SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.

SeaSpine Holdings Corporation

Esaote focuses on medical diagnostic imaging, specifically in ultrasound, MRI, and healthcare IT, self-described as contributing to better quality healthcare.

Esaote

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Sequana Medical NV

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Bioventus Inc.

SeaSpine provides procedural solutions and innovative products for spine and orthopedic surgeries, focusing on improving surgical outcomes and patient lives.

Metric
Company Name	SeaSpine Holdings Corporation	Esaote	Sequana Medical NV	Bioventus Inc.
Symbol	SPNE		SEQUA	BVS
MSH ID	COM:SEASPINE	COM:ESAOTE	COM:SEQUANAMEDICAL	COM:BIOVENTUS
Market	STOCKS	PRIVATE	STOCKS	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare
Industry	Medical - Devices	Medical Devices	Medical - Devices	Medical - Devices
Country	US	IT	BE	US
Stage
Employee Count	523	1.00K	62	995
Website	seaspine.com	esaote.com	sequanamedical.com	bioventus.com
LinkedIn
Founders

Metric
Market Cap			42.61M	375.94M
Enterprise Value
Monthly Web Traffic	1.86K	35.69K
Web Traffic Growth	-0.23	-0.52
Valuation
Raised Capital

Metric
Revenue	191.45M	752.04K	512.35M
Revenue (LTM)
Revenue (NTM)
Gross Profit	114.59M	-4.39M	319.35M
EBITDA	-55.45M	-30.45M	73.38M
Operating Income	-60.98M	-31.15M	16.01M
Net Income	-54.35M	-34.40M	-156.23M
EPS	-1.62	-1.29	-2.49
Diluted EPS	-1.62	-1.29	-2.49
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.60	0.77	0.66
Operating Profit Margin	-0.32	-36.21	0.16
EBITDA Margin	-0.29	-40.49	0.14
Net Profit Margin	-0.28	-38.43	-0.04
Return on Equity	-0.22	16.85	-0.12
Return on Assets	-0.14	-1.93	-0.03
Return on Capital Employed	-0.19	4.68	0.13

COM:SEASPINE

SeaSpine

Last Close

8.81

04/01 21:00

Volume Today

1.16M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-7.67	-2.94	-1.82
P/B Ratio	1.29	-41.98	1.60
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		103.14	1.57
EV Multiple	-1.35	-0.21	6.83

Metric
Days Sales Outstanding	81.67		81.96
Days Payables Outstanding	98.11	5.76K	34.49
Days Inventory Outstanding	343.32	7.30K	194.34
Operating Cycle	412.40	7.58K	282.00
Cash Conversion Cycle	315.99	1.05K	243.73
Asset Turnover	0.51	0.11	0.68

Metric
Operating Cash Flow	-33.51M	-31.68M	15.34M
Free Cash Flow	-59.55M	-32.43M	7.98M
Cash Flow to Debt	-4.14	-1.15	0.04
Operating Cash Flow/Sales	-0.18	-36.33	0.03
Free Cash Flow Yield		-0.25	-0.00

Metric
Cash & Equivalents	83.11M	2.73M	36.96M
Accounts Receivable	-7.93M	-573.53K	10.05M
Inventory	72.30M	2.43M	91.33M
Goodwill	84.59M		7.46M
Debt to Capitalization	0.03	9.85	0.72
Debt to Assets	0.12	0.68	0.49
Current Ratio	3.18	1.52	1.55
Quick Ratio	2.25	1.28	0.97

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06	0.61	0.01
R&D to Revenue	0.10		0.03
SG&A to Revenue	0.22	7.25